Total
0
Shares
AusCann (ASX:AC8) - CEO, Layton Mills
CEO, Layton Mills
Source: Layton Mills / LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • AusCann Group (AC8) begins designing a clinical discovery trial to evaluate its cannabinoid-based formulation in people with spinal cord injury (SCI)
  • Spinal cord injury occurs when there is damage to any part of the spinal cord or nerves at the end of the spinal cord
  • Data from the trial may be used to support a more extensive human drug development program for marketing approval via the US Food and Drug Administration
  • The trial will begin once approval is received by the human research ethics committee (HREC) with a submission expected to be made early next year
  • AusCann is up 5.26 per cent on the market with shares trading at 10 cents

AusCann Group (AC8) has begun designing a clinical discovery trial to evaluate its cannabinoid-based formulation in people with spinal cord injury (SCI).

Spinal cord injury occurs when there is damage to any part of the spinal cord or nerves at the end of the spinal cord. This may occur when a sudden blow or cut to the spine occurs.

People with a SCI often experience a permanent loss of strength, sensation and function below the site of the injury.

Current treatment includes supportive care, medication, surgery or therapy.

This trial follows the completion of a technical assessment for the use of cannabinoids associated with SCI.

The overall aim is to generate clinical data on the benefits of AusCann’s cannabinoid-based formulations for people suffering from SCI.

The data may then be used to support a more extensive human drug development program for marketing approval via the US Food and Drug Administration.

The trial will begin once approval is received by the human research ethics committee (HREC) with a submission expected to be made early next year.

Additionally, the trial will be led by renowned pain specialist Dr Marc Russo.

Upon completion of the trial, AusCann will withdraw from its investigator-led trial to redirect its resource to a research and development program to support product registration in targeted medical conditions.

AusCann was up 5.26 per cent on the market with shares trading at 10 cents at 12:34 pm AEDT.

AC8 by the numbers
More From The Market Herald

" Petratherm (ASX:PTR) begins drilling at Comet

Pertatherm (PTR) has started prospect drilling at the Comet Gold Project in South Australia.

" Australian Dairy Nutritionals (ASX:AHF) and Wellnex Life (ASX:WNX) to launch organic A2 infant formula

Australian Dairy Nutritionals (AHF) and Wellnex Life (WNX) have established a joint venture to launch Australia’s first organic A2 protein infant formula.

" Cooper Metals (ASX:CPM) encouraged by rock chip assays at Mt Isa East

Cooper Metals (CPM) has released the last batch of results from rock chip geochemical sampling at the Mt Isa East project in Queensland.
Cirrus Networks (ASX:CNW) - CEO & Managing Director, Chris McLaughlin

" Cirrus Networks (ASX:CNW) signs partnership with global IT cloud security company

Cirrus (CNW) has signed a partnership with Gigamon to provide managed security services to governments and large enterprises.